Evaluation of chiral purity for a substituted imidazole p38 MAP kinase inhibitor and its intermediates using a single chiral capillary electrophoresis method.
The chiral separation of a substituted imidazole p38 MAP kinase inhibitor and its intermediates was investigated using capillary electrophoresis (CE) with various sulfated cyclodextrins. After initial screens, a single CE chiral method with a randomly sulfated beta-CD was selected for the evaluation of chiral purity for all three compounds. Operational parameters, such as the concentration of the chiral selectors, background electrolyte (or mobile phase) pH, organic modifiers, and temperature were varied in order to achieve an optimized method. The optimal method was validated in terms of linearity, sensitivity, precision, ruggedness, and specificity.
Zhou
Lili
L
Merck Research Laboratories, Merck and Co. Inc., Rahway, NJ 07065, USA. lili_zhou@merck.com
Thompson
Richard
R
Ellison
Dean
D
Wyvratt
Jean M
JM
D000097:Acetonitriles; D019075:Electrophoresis, Capillary / Q000379:methods*; D004791:Enzyme Inhibitors / Q000737:chemistry* / Q000302:isolation & purification*; D006863:Hydrogen-Ion Concentration; D007093:Imidazoles / Q000737:chemistry* / Q000302:isolation & purification*; D007202:Indicators and Reagents; D015394:Molecular Structure; D012996:Solutions; D013237:Stereoisomerism; D013696:Temperature; D047392:beta-Cyclodextrins / Q000737:chemistry; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*
D000097:Acetonitriles; D004791:Enzyme Inhibitors; D007093:Imidazoles; D007202:Indicators and Reagents; D012996:Solutions; D047392:beta-Cyclodextrins; D048051:p38 Mitogen-Activated Protein Kinases; C031215:betadex; C032159:acetonitrile